Momenta Pharmaceuticals, Inc. (MNTA) Director Elizabeth Stoner Sells 3,399 Shares

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Director Elizabeth Stoner sold 3,399 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $19.00, for a total value of $64,581.00. Following the completion of the transaction, the director now owns 21,176 shares of the company’s stock, valued at approximately $402,344. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Elizabeth Stoner also recently made the following trade(s):

  • On Tuesday, April 10th, Elizabeth Stoner sold 3,399 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $19.00, for a total value of $64,581.00.
  • On Tuesday, January 30th, Elizabeth Stoner sold 16,264 shares of Momenta Pharmaceuticals stock. The stock was sold at an average price of $18.00, for a total value of $292,752.00.

Shares of NASDAQ MNTA traded down $0.33 during trading on Friday, reaching $19.37. 32,096 shares of the company traded hands, compared to its average volume of 891,457. Momenta Pharmaceuticals, Inc. has a 12-month low of $11.85 and a 12-month high of $20.25.



Momenta Pharmaceuticals (NASDAQ:MNTA) last released its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.18 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.12. The business had revenue of $64.60 million during the quarter, compared to analyst estimates of $66.59 million. Momenta Pharmaceuticals had a negative return on equity of 23.62% and a negative net margin of 63.43%. The company’s revenue was up 88.9% on a year-over-year basis. During the same quarter last year, the business posted $0.60 EPS. analysts forecast that Momenta Pharmaceuticals, Inc. will post -1.27 EPS for the current year.

A number of equities analysts recently issued reports on the company. BidaskClub upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, April 4th. ValuEngine upgraded Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd. Stifel Nicolaus restated a “hold” rating and issued a $18.00 target price on shares of Momenta Pharmaceuticals in a research note on Tuesday, January 30th. Finally, Zacks Investment Research upgraded Momenta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $15.33.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in MNTA. Tocqueville Asset Management L.P. raised its stake in shares of Momenta Pharmaceuticals by 243.6% during the 4th quarter. Tocqueville Asset Management L.P. now owns 963,784 shares of the biotechnology company’s stock valued at $13,445,000 after buying an additional 683,296 shares during the last quarter. Renaissance Technologies LLC raised its stake in shares of Momenta Pharmaceuticals by 9.3% during the 4th quarter. Renaissance Technologies LLC now owns 1,583,000 shares of the biotechnology company’s stock valued at $22,083,000 after buying an additional 134,500 shares during the last quarter. Sectoral Asset Management Inc raised its stake in shares of Momenta Pharmaceuticals by 34.3% during the 4th quarter. Sectoral Asset Management Inc now owns 500,298 shares of the biotechnology company’s stock valued at $6,979,000 after buying an additional 127,799 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Momenta Pharmaceuticals by 224.8% during the 4th quarter. Arizona State Retirement System now owns 128,388 shares of the biotechnology company’s stock valued at $1,791,000 after buying an additional 88,854 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Momenta Pharmaceuticals by 0.8% during the 4th quarter. BlackRock Inc. now owns 10,473,316 shares of the biotechnology company’s stock valued at $146,105,000 after buying an additional 82,691 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

TRADEMARK VIOLATION WARNING: This news story was published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright laws. The legal version of this news story can be accessed at https://dakotafinancialnews.com/2018/04/13/momenta-pharmaceuticals-inc-mnta-director-elizabeth-stoner-sells-3399-shares.html.

Momenta Pharmaceuticals Company Profile

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for autoimmune diseases in the United States. The company's complex generics programs include Enoxaparin sodium injection, a generic version of Lovenox that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing-remitting multiple sclerosis; and GLATOPA, a generic product candidate for three-times-weekly COPAXONE.

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply